公开(公告)号：US10344024B2

公开(公告)日：2019-07-09

申请号：US15956168

申请日：2018-04-18

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Sanjib Das ,  Laxmikant A. Gharat ,  Rajendra L. Harde ,  Sandeep Y. Shelke ,  Shailesh R. Pardeshi ,  Abraham Thomas ,  Neelima Khairatkar-Joshi ,  Daisy M. Shah ,  Malini Bajpai

IPC: C07D241/18 ,  C07D241/20 ,  C07D401/04 ,  C07D403/04 ,  C07D417/12 ,  C07D231/12 ,  C07D239/26 ,  C07D239/36 ,  C07D239/42 ,  C07D413/04 ,  C07D413/12 ,  C07D213/40 ,  C07D241/12 ,  C07D405/14

Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

公开(公告)号：US20180237428A1

公开(公告)日：2018-08-23

申请号：US15956168

申请日：2018-04-18

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Sanjib Das ,  Laxmikant A. Gharat ,  Rajendra L. Harde ,  Sandeep Y. Shelke ,  Shailesh R. Pardeshi ,  Abraham Thomas ,  Neelima Khairatkar-Joshi ,  Daisy M. Shah ,  Malini Bajpai

IPC: C07D417/12 ,  C07D213/40 ,  C07D413/12 ,  C07D413/04 ,  C07D239/42 ,  C07D239/36 ,  C07D241/18 ,  C07D403/04 ,  C07D401/04 ,  C07D231/12 ,  C07D405/14 ,  C07D241/20 ,  C07D241/12 ,  C07D239/26

CPC classification number: C07D417/12 ,  C07D213/40 ,  C07D231/12 ,  C07D239/26 ,  C07D239/36 ,  C07D239/42 ,  C07D241/12 ,  C07D241/18 ,  C07D241/20 ,  C07D401/04 ,  C07D403/04 ,  C07D405/14 ,  C07D413/04 ,  C07D413/12

Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related Sorphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

公开(公告)号：US10336688B2

公开(公告)日：2019-07-02

申请号：US16204977

申请日：2018-11-29

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Sanjib Das ,  Laxmikant A. Gharat ,  Rajendra L. Harde ,  Dnyaneshwar E. Shelke ,  Shailesh R. Pardeshi ,  Abraham Thomas ,  Neelima Khairatkar-Joshi ,  Daisy M. Shah ,  Malini Bajpai

IPC: C07C237/42 ,  A61P11/14 ,  A61P11/08 ,  A61P17/06 ,  A61P11/06

Abstract: The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Ra, Rb, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

公开(公告)号：US10189775B2

公开(公告)日：2019-01-29

申请号：US15754037

申请日：2016-08-26

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Sanjib Das ,  Laxmikant A. Gharat ,  Rajendra L. Harde ,  Dnyaneshwar E. Shelke ,  Shailesh R. Pardeshi ,  Abraham Thomas ,  Neelima Khairatkar-Joshi ,  Daisy M. Shah ,  Malini Bajpai

IPC: C07C237/42 ,  A61P11/06 ,  A61P11/08 ,  A61P11/14 ,  A61P17/06

Abstract: The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Ra, Rb, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

公开(公告)号：US20180237382A1

公开(公告)日：2018-08-23

申请号：US15754037

申请日：2016-08-26

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Sanjib Das ,  Laxmikant A. Gharat ,  Rajendra L. Harde ,  Dnyaneshwar E. Shelke ,  Shailesh R. Pardeshi ,  Abraham Thomas ,  Neelima Khairatkar-Joshi ,  Daisy M. Shah ,  Malini Bajpai

IPC: C07C237/42 ,  A61P11/06 ,  A61P11/08 ,  A61P17/06 ,  A61P11/14

CPC classification number: C07C237/42 ,  A61P11/06 ,  A61P11/08 ,  A61P11/14 ,  A61P17/06 ,  C07B2200/07 ,  C07C2601/02 ,  C07C2601/16

Abstract: The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Ra, Rb, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

公开(公告)号：US09975887B2

公开(公告)日：2018-05-22

申请号：US15318513

申请日：2016-08-02

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Sanjib Das ,  Laxmikant A. Gharat ,  Rajendra L. Harde ,  Sandeep Y. Shelke ,  Shailesh R. Pardeshi ,  Abraham Thomas ,  Neelima Khairatkar-Joshi ,  Daisy M. Shah ,  Malini Bajpai

IPC: A61K31/497 ,  A61K31/4427 ,  A61K31/4965 ,  C07D241/18 ,  C07D241/20 ,  C07D401/04 ,  C07D403/04 ,  C07D417/12 ,  C07D231/12 ,  C07D239/26 ,  C07D239/36 ,  C07D239/42 ,  C07D413/04 ,  C07D413/12 ,  C07D213/40 ,  C07D241/12 ,  C07D405/14

CPC classification number: C07D417/12 ,  C07D213/40 ,  C07D231/12 ,  C07D239/26 ,  C07D239/36 ,  C07D239/42 ,  C07D241/12 ,  C07D241/18 ,  C07D241/20 ,  C07D401/04 ,  C07D403/04 ,  C07D405/14 ,  C07D413/04 ,  C07D413/12

Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

公开(公告)号：US10988467B2

公开(公告)日：2021-04-27

申请号：US16402948

申请日：2019-05-03

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Sanjib Das ,  Laxmikant A. Gharat ,  Rajendra L. Harde ,  Sandeep Y. Shelke ,  Shailesh R. Pardeshi ,  Abraham Thomas ,  Neelima Khairatkar-Joshi ,  Daisy M. Shah ,  Malini Bajpai

IPC: C07D241/18 ,  C07D401/04 ,  C07D403/04 ,  C07D417/12 ,  C07D231/12 ,  C07D239/26 ,  C07D239/36 ,  C07D239/42 ,  C07D413/04 ,  C07D413/12 ,  C07D213/40 ,  C07D241/12 ,  C07D241/20 ,  C07D405/14

Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

公开(公告)号：US20190256508A1

公开(公告)日：2019-08-22

申请号：US16402948

申请日：2019-05-03

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Sanjib Das ,  Laxmikant A. Gharat ,  Rajendra L. Harde ,  Sandeep Y. Shelke ,  Shailesh R. Pardeshi ,  Abraham Thomas ,  Neelima Khairatkar-Joshi ,  Daisy M. Shah ,  Malini Bajpai

IPC: C07D417/12 ,  C07D213/40 ,  C07D413/12 ,  C07D413/04 ,  C07D239/42 ,  C07D239/36 ,  C07D239/26 ,  C07D241/18 ,  C07D401/04 ,  C07D231/12 ,  C07D405/14 ,  C07D241/20 ,  C07D241/12 ,  C07D403/04

Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

公开(公告)号：US20190144375A1

公开(公告)日：2019-05-16

申请号：US16204977

申请日：2018-11-29

Applicant: Glenmark Pharmaceuticals S.A.

Inventor： Sanjib Das ,  Laxmikant A. Gharat ,  Rajendra L. Harde ,  Dnyaneshwar E. Shelke ,  Shailesh R. Pardeshi ,  Abraham Thomas ,  Neelima Khairatkar-Joshi ,  Daisy M. Shah ,  Malini Bajpai

IPC: C07C237/42 ,  A61P11/14 ,  A61P11/08 ,  A61P11/06 ,  A61P17/06

CPC classification number: C07C237/42 ,  A61P11/06 ,  A61P11/08 ,  A61P11/14 ,  A61P17/06 ,  C07B2200/07 ,  C07C2601/02 ,  C07C2601/16

Abstract: The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Ra, Rb, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.